EA201990978A1 - ANTIBODIES AGAINST PD-1 - Google Patents

ANTIBODIES AGAINST PD-1

Info

Publication number
EA201990978A1
EA201990978A1 EA201990978A EA201990978A EA201990978A1 EA 201990978 A1 EA201990978 A1 EA 201990978A1 EA 201990978 A EA201990978 A EA 201990978A EA 201990978 A EA201990978 A EA 201990978A EA 201990978 A1 EA201990978 A1 EA 201990978A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
present
provides
antibodies against
bind
Prior art date
Application number
EA201990978A
Other languages
Russian (ru)
Inventor
Алекс Дункан
Мэттью Маккорт
Майкл Дайсон
Джон Блэквуд
Original Assignee
Актиджен Лтд
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Актиджен Лтд filed Critical Актиджен Лтд
Publication of EA201990978A1 publication Critical patent/EA201990978A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

В соответствии с настоящем изобретением предложены антитела, которые связываются с PD-1. Настоящее изобретение также предлагает иммуноконъюгаты и композиции, содержащие такие антитела. В соответствии с настоящим изобретением также предложены способы получения таких антител. В настоящем изобретении дополнительно предложено применение таких антител для целей терапии и диагностики.The present invention provides antibodies that bind to PD-1. The present invention also provides immunoconjugates and compositions comprising such antibodies. In accordance with the present invention also provides methods for producing such antibodies. The present invention further provides the use of such antibodies for the purposes of therapy and diagnosis.

EA201990978A 2016-11-08 2017-11-08 ANTIBODIES AGAINST PD-1 EA201990978A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201618833 2016-11-08
PCT/EP2017/078595 WO2018087143A2 (en) 2016-11-08 2017-11-08 Anti-pd-1 antibodies

Publications (1)

Publication Number Publication Date
EA201990978A1 true EA201990978A1 (en) 2019-12-30

Family

ID=60388022

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201990978A EA201990978A1 (en) 2016-11-08 2017-11-08 ANTIBODIES AGAINST PD-1

Country Status (2)

Country Link
EA (1) EA201990978A1 (en)
WO (1) WO2018087143A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017011580A2 (en) 2015-07-13 2017-01-19 Cytomx Therapeutics, Inc. Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
BR112021013157A8 (en) * 2019-01-03 2022-12-06 Inst Nat Sante Rech Med USES OF AN NRP-1 INHIBITOR, USE OF A COMBINATION, USE OF A MULTIESPECIFIC ANTIBODY, EX VIVO METHOD TO PREDICT, USE OF AN INHIBITOR, MULTIESPECIFIC ANTIBODY, MODIFIED CELL POPULATION, EX VIVO METHOD OF PRODUCTION AND USE OF A POPULATION OF T CELLS
WO2021006199A1 (en) 2019-07-05 2021-01-14 小野薬品工業株式会社 Treatment of hematologic cancer with pd-1/cd3 dual specificity protein
US20220332825A1 (en) 2019-08-08 2022-10-20 Ono Pharmaceutical Co., Ltd. Bispecific protein

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201500464D0 (en) * 2015-01-12 2015-02-25 Crescendo Biolog Ltd Method of producing optimised therapeutic molecules

Also Published As

Publication number Publication date
WO2018087143A3 (en) 2018-12-13
WO2018087143A2 (en) 2018-05-17

Similar Documents

Publication Publication Date Title
EA202091540A1 (en) ANTIBODIES TO LILRB2
CY1122840T1 (en) HUMANIZED OR CHIMERIC CD3 ANTIBODIES
MX2017013613A (en) Cancer neoepitopes.
MY195110A (en) Antibodies to PD-1 and uses Thereof
EA202090104A1 (en) ANTIBODY MOLECULES TO CD73 AND WAYS OF THEIR APPLICATION
EA201791485A1 (en) ANTI-CD47-ANTIBODIES AND THEIR APPLICATIONS
EA201891983A8 (en) COMBINED THERAPY BY ANTIBODIES TO CD73
EA201892294A1 (en) ANTIBODIES AND COMPOSITIONS AGAINST TIM-3
EA201890285A1 (en) ANTIBODIES AGAINST PD-1, ACTIVATED ANTIBODIES AGAINST PD-1 AND METHODS OF THEIR APPLICATION
SA517381703B1 (en) Anti-C10orf54 Antibodies And Uses Thereof
EA201691824A1 (en) ANTIBODIES AGAINST EGFRVIII AND THEIR APPLICATIONS
EA201791093A1 (en) ANTIBODIES TO CD47, METHODS AND USE
EA201790413A1 (en) ANTIBODIES AGAINST TIGIT
EA201890131A1 (en) IMMUNOMODULATION AND TREATMENT OF SOLID TUMORS BY ANTIBODIES THAT SPECIFICALLY CONNECT CD38
EA201792221A1 (en) ANTIBODIES AGAINST SORTILINE AND METHODS OF THEIR APPLICATION
MX2018008934A (en) Anti-ror1 antibodies, ror1 x cd3 bispecific antibodies, and methods of using the same.
EA201890145A1 (en) ANTIBODIES TO FACTOR XI AND METHODS OF THEIR APPLICATION
EA201890453A1 (en) ANTI-ANGPTL8 ANTIBODIES AND THEIR APPLICATION
EA201991214A1 (en) ANTIBODIES AGAINST PD-1 AND THEIR COMPOSITION
MX2017004311A (en) Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof.
EA201790569A1 (en) ANTIBODIES AND IMMUNOCONJUGATES AGAINST CLL-1
EA201890305A1 (en) HUMANIZED OR CHIMERIC CD3 ANTIBODIES
EA201790545A1 (en) ANTIBODIES AND IMMUNOCONJUGATES AGAINST HER2
EA201691488A1 (en) ANTIBODY MOLECULES AGAINST PD-1 AND THEIR APPLICATIONS
EA201790273A1 (en) FLAGELLIN COMPOSITIONS AND THEIR APPLICATION